Atrys Health Accelerates Growth and Slashes Debt in First Half of 2026

Atrys Health reported first-half 2026 revenues of 77.7 million euros, up 9.4% year on year, and EBITDA of 9.3 million euros, up 21.3%, with underlying EBITDA growth exceeding 44%.

Performance was driven by strong expansion in Oncology and Nuclear Medicine and robust international growth, notably in Latin America and Portugal, alongside a 79.2% reduction in net financial debt after the sale of ASPY, sharply improving cash generation and lowering financing costs.

By division, Oncology revenue grew 22.5% to 37.1 million euros and Nuclear Medicine posted double-digit sales and triple-digit EBITDA growth, supported by efficiency measures and network expansion.

Geographically, Latin America led with 26.1% growth and a surge in Mexico’s oncology business, while Portugal and Spain delivered solid gains, reinforcing Atrys’s strategic focus on high-value diagnostic and treatment services.

The company is rolling out a new organizational model to boost operational efficiency and remains on track to meet its 2026 targets, including double-digit revenue growth, a 40% rise in EBITDA and a more balanced capital structure aligned with its 2026–2028 strategic plan.

This story was written using TipRanks’s AI tools and reviewed by a TipRanks editor.…Read more by TipRanks Spain Auto-Generated Newsdesk